Coronary Artery Disease and Oxidative Stress

Benfato, Mara da Silveira; Medeiros, Tássia Machado; Salomon, Tiago Boeira

doi:10.5772/29822

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients can present with varying degrees of nausea, chest tightness, chest pain and dyspnea, and even death due to cardiac arrest. [3] As a result of the increasing morbidity and mortality, CHD has become an important global public health problem. In recent years, the COVID-19 pandemic has directly or indirectly increased the burden of CVD, putting those who suffer from CHD at a higher risk of dying.…”

Section: Introductionmentioning

confidence: 99%

Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis

Li,

Song,

Rong

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Coronary heart disease (CHD) is a type of cardiovascular disease (CVD) caused by coronary atherosclerosis. It is a main cause of medical burden and cardiovascular related death. Zhishi Xiebai Guizhi Decoction (ZXGD) is a representative prescription of traditional Chinese medicine (TCM) in the treatment of CHD, but there is poor systemically evidence-based appraisal. Objective: To evaluate the efficacy and safety of ZXGD for CHD. Methods: Eight databases were retrieved for randomized controlled trials (RCTs). Data was extracted independently by 2 reviewers. The quality of the included studies was assessed by Cochrane Collaboration risk of bias tool. Clinical efficacy, blood lipid, vascular endothelial function, inflammatory factor and homocysteine (Hcy) were prespecified outcome measures. Results: Twenty-four studies (2272 patients) were included. Meta-analysis showed that compared with conventional western medicine (WM) alone, ZXGD was associated with a greater symptom improvement rate with a relative risk (RR) of 1.21 [95% CI (1.16, 1.26), P < .00001] and a greater electrocardiogram (ECG) improvement rate with a RR of 1.27 [95% CI (1.16, 1.40), P < .00001]. In terms of blood lipid, ZXGD reduced total cholesterol (TC) with a mean difference (MD) of −1.15 [95%CI (−1.75, −0.55), P = .0002] and triglyceride (TG) [MD = −0.72, 95%CI (−0.99, −0.45), P < .00001], reduced low-density lipoprotein cholesterol (LDL-C) [MD = −0.93, 95% CI (−1.17, −0.69), P < .00001], and increased high-density lipoprotein cholesterol (HDL-C) [MD = 0.31, 95%CI (0.20, 0.42), P < .00001]. In terms of vascular endothelial function, ZXGD decreased the level of endothelin-1 (ET-1) [MD = −7.81, 95%CI (−9.51, −6.10), P < .00001], and increased nitric oxide (NO) [MD = 8.90, 95%CI (7.86, 9.93), P < .00001]. ZXGD also reduced high-sensitivity C-reactive protein (hs-CRP) [MD = −1.73, 95% CI (−2.63, −0.83), P < .00001] and Hcy [MD = −2.03, 95%CI (−2.78, −1.28), P < .00001]. No significant differences were found in adverse event rate between the 2 groups with a RR of 0.77 [95% CI (0.44, 1.34), P = .36]. Conclusion: ZXGD is effective and safe in the treatment of CHD. However, more rigorous and high-quality RCTs are needed to verify the conclusion.

show abstract

Section: Introductionmentioning

confidence: 99%